Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse-Reference-Cited by-同舟云学术

Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse

Published:2019-12-01 Issue:6 Volume:40 Page:243-250
ISSN:0388-6107
Container-title:Biomedical Research
language:en
Short-container-title:Biomed. Res.

Author:

ASHIZAWA Tadashi¹,IIZUKA Akira¹,TANAKA Emiko¹,KONDOU Ryota¹,MIYATA Haruo¹,MAEDA Chie¹,SUGINO Takashi²,YAMAGUCHI Ken³,ANDO Takayuki⁴,ISHIKAWA Yoshinobu⁵,ITO Mamoru⁶,AKIYAMA Yasuto¹

Affiliation:

1. Immunotherapy Division, Shizuoka Cancer Center Research Institute

2. Division of Pathology, Shizuoka Cancer Center Hospital

3. Office of the president, Shizuoka Cancer Center Hospital

4. Shizuoka Institute of the Environment and Hygiene

5. School of Pharmaceutical Sciences, University of Shizuoka

6. Central Institute for Experimental Animals

Publisher

Biomedical Research Press

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.jstage.jst.go.jp/article/biomedres/40/6/40_243/_pdf

Reference33 articles.

1. 1 Abdel-Magid AF (2015) Inhibitors of the PD-1/PD-L1 pathway can mobilize the immune system: an innovative potential therapy for cancer and chronic infections. ACS Med Chem Lett 6, 489–490.

2. 2 Akiyama Y, Nonomura C, Kondou R, Miyata H, Ashizawa T, Maeda C, Mitsuya K, Hayashi N, Nakasu Y and Yamaguchi K (2016) Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. Int J Oncol 49, 1099–1107.

3. 3 Akiyama Y, Nonomura C, Ashizawa T, Iizuka A, Kondou R, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, et al. (2017) The anti-tumor activity of the STAT3 inhibitor STX0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line. Immunol Lett 190, 20–25.

4. 4 Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu et al. (2017) Antitumor effect of programmed death-1 (PD-1) blockade in humanized the NOG-MHC double knockout mouse. Clin Cancer Res 23, 149–158.

5. 5 Basu S, Yang J, Xu B, Magiera-Mularz K, Skalniak L, Musielak B, Kholodovych V, Holak TA and Hu L (2019) Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein interaction. J Med Chem 62, 7250–7263.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade;Phytomedicine;2024-03

2. Inhibition of UV-Induced Stress Signaling and Inflammatory Responses in SKH-1 Mouse Skin by Topical Small Molecule PD-L1 Blockade;JID Innovations;2024-01

3. PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer;Journal of Nanobiotechnology;2023-12-11

4. Interrogating ligand-receptor interactions using highly sensitive cellular biosensors;Nature Communications;2023-11-28

5. Ce6 nanoassemblies: Molecular mechanism and strategies for combinational anticancer therapy;Aggregate;2023-10-12